Doctors in Dallas and other parts of Texas are beginning to use a new blood test that can detect colon cancer earlier. The ...

London – M42, a global health leader powered by artificial intelligence (AI), and Hikma Pharmaceuticals PLC (Hikma), ...

北京时间2025年02月01日03时00分，Guardant Health, Inc.（GH.us）股票出现异动，股价急速下挫5.07%。截至发稿，该股报47.41美元/股，成交量137.507万股，换手率1.11%，振幅4.67%。

The introduction of the Shield™ test for colorectal cancer screening marks a transformative step in advancing precision and ...

Guardant Health (GH) announced an agreement with the Abu Dhabi Public Health Center ADPHC to introduce a non-invasive blood-based screening ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced an agreement with the Abu Dhabi ...

A novel blood-based test for early detection of colorectal cancer in average-risk adults met the primary endpoints of ...

PALO ALTO, Calif. - Guardant Health , Inc. (NASDAQ: NASDAQ:GH), a precision oncology company with a market capitalization of $5.8 billion, has presented new data at the American Society of ...

周二，Raymond James确认维持Guardant Health (NASDAQ:GH)的"跑赢大市"评级，目标价保持在39.00美元不变。该公司股票表现强劲，过去一年回报率达58%，目前交易价格接近52周高点。根据InvestingPro分析，该公司分析师强调了Reveal产品以及更广泛产品组合在销量和平均售价(ASP ...

BTIG raised the price target for Guardant Health (NASDAQ:GH) to $55.00, up from the previous target of $50.00, while ...

周二，BTIG将Guardant Health（纳斯达克股票代码：GH）的目标价从此前的50.00美元上调至55.00美元，同时维持对该股的买入评级。此次调整是在Guardant Health股价当天上午飙升15%之后做出的，原因是该公司宣布其Guardant Reveal ...